Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$2.13M | -$1.81M | -$2.14M | -$2.49M | -$3.27M | -$6.72M | -$6.31M | -$5.09M | -$3.57M | -$5.11M |
| Net income | -$2.13M | -$1.81M | -$2.13M | -$2.44M | -$3.26M | -$6.73M | -$6.31M | -$5.09M | -$3.59M | -$6.08M |
| EPS (diluted) | -$0.04 | -$0.03 | -$0.04 | -$0.22 | -$0.29 | -$0.50 | -$3.99 | -$2.66 | -$1.59 | -$1.26 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.68M | -$1.41M | -$1.51M | $1.67M | -$2.13M | -$4.14M | -$4.61M | -$4.29M | -$3.16M | -$3.07M |
| Share buybacks | — | — | $24.7K | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $200K | $1.31M | $4.27M | $2.60M | $5.07M | $4.82M | $5.35M | $4.20M | — | — |
| Total assets | $433K | $1.37M | $4.34M | $2.67M | $5.23M | $5.09M | $5.56M | $4.31M | $1.15M | $12.7M |
| Total liabilities | $219K | — | — | — | — | — | — | — | $318K | $1.77M |
| Shareholders' equity | $215K | $995K | $4.13M | $2.43M | $5.01M | $4.79M | $5.17M | $3.99M | $827K | $9.66M |
| Retained earnings | -$20.7M | -$22.5M | -$24.6M | -$27.1M | -$30.4M | -$37.1M | -$43.4M | -$48.5M | -$52.1M | -$58.1M |
| Shares (wtd avg diluted) | 47.9M | 58.0M | 67.0M | 11.2M | 12.4M | 13.7M | 1.58M | 1.92M | 2.25M | 4.84M |
Every figure is extracted from LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.